Want to see QNTM full AI Analyst Report?
QNTM Stock Chart & Stats
$3.28
-$0.02(-0.67%)
At close: 4:00 PM EDT
$3.28
-$0.02(-0.67%)
Day’s Range― - ―
52-Week Range$2.07 - $14.86
Previous Close$2.97
Volume31.71K
Average Volume (3M)185.83K
Market Cap
$19.65M
Enterprise Value$13.44M
Total Cash (Recent Filing)$9.73M
Total Debt (Recent Filing)$962.16K
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.65
Shares Outstanding8,087,479
10 Day Avg. Volume113,565
30 Day Avg. Volume185,829
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.47
Price to Sales (P/S)0.00
P/FCF Ratio-2.86
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-53.59
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$8.00Price Target Upside143.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.85
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 2 Clinical ProgressRegulatory clearance and operational trial preparation move Lucid-MS from development planning into clinical execution. The differentiated PAD2-focused neuroprotective approach gives Quantum a defined opportunity in progressive multiple sclerosis, where the company identifies substantial unmet need.
Liquidity And Cost DisciplineImproved liquidity and lower operating expenses provide greater capacity to fund the clinical program before additional financing is required. A longer stated runway reduces near-term funding pressure and gives management more time to generate meaningful development data.
Modest LeverageRelatively modest and declining leverage limits immediate balance-sheet strain compared with a more debt-heavy development company. This provides some financial flexibility while Quantum advances its pipeline, although the benefit is partly offset by continuing losses and capital erosion.
Bears Say
Pre-Revenue Loss ProfileQuantum has not yet established operating revenue, while substantial losses continue across historical and trailing periods. This leaves the company dependent on successful clinical development and future financing or transactions rather than an internally funded commercial business model.
Persistent Cash BurnPersistent negative operating and free cash flow means the business continues consuming capital to operate and develop its assets. Even with recent improvement in operating cash flow, ongoing burn can constrain investment choices and increase reliance on external funding.
Capital ErosionMaterial equity erosion indicates that historical funding has not translated into shareholder returns and has reduced the balance-sheet cushion. Continued losses or dilution could further weaken financial flexibility, making future pipeline progress increasingly dependent on capital-market access.
Quantum Biopharma News
QNTM FAQ
What was Quantum Biopharma’s price range in the past 12 months?
Quantum Biopharma lowest stock price was $2.07 and its highest was $14.86 in the past 12 months.
What is Quantum Biopharma’s market cap?
Quantum Biopharma’s market cap is $19.65M.
When is Quantum Biopharma’s upcoming earnings report date?
Quantum Biopharma’s upcoming earnings report date is Nov 06, 2026 which is in 13 days.
How were Quantum Biopharma’s earnings last quarter?
Quantum Biopharma released its earnings results on Aug 13, 2026. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.05.
Is Quantum Biopharma overvalued?
According to Wall Street analysts Quantum Biopharma’s price is currently Undervalued.
Does Quantum Biopharma pay dividends?
Quantum Biopharma does not currently pay dividends.
What is Quantum Biopharma’s EPS estimate?
Quantum Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Quantum Biopharma have?
Quantum Biopharma has 8,087,479 shares outstanding.
What happened to Quantum Biopharma’s price movement after its last earnings report?
Quantum Biopharma reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went up 17.647%.
Which hedge fund is a major shareholder of Quantum Biopharma?
Currently, no hedge funds are holding shares in QNTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quantum Biopharma
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
QNTM Stock 12 Month Forecast
Average Price Target
$8.00
▲(143.90% Upside)
Technical Analysis
Ownership Overview
10.68% Insiders
<0.01% Other Institutional Investors
84.72% Public Companies and
Individual Investors